Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) (NCT04170153)
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and early signs of efficacy of Tuvuseritib (M1774) as monotherapy and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Massachusetts General Hospital — Boston, Massachusetts
- NEXT Oncology — Austin, Texas
- Mary Crowley Cancer Research Centers — Dallas, Texas
- The Methodist Hospital Research Institute — Houston, Texas
- University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics — Houston, Texas
- Beijing Cancer Hospital — Beijing,
- National Cancer Center Hospital - Dept of Experimental Therapeutics — Chūōku,
- National Cancer Center Hospital East - Dept of Experimental Therapeutics — Kashiwa-shi,
- Hospital Clinic de Barcelona - Servicio de Oncologia — Barcelona,
- Hospital Universitari Vall d'Hebron - Oncology Dept. — Barcelona,
- Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica — Madrid,
- Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica — Valencia,
- Addenbrooke's Hospital - Dept of Oncology — Cambridge,
- The Christie Hospital - Dept of Oncology — Manchester,
- Northern Centre for Cancer Care - Sir Bobby Robson Cancer Trials Research Centre — Newcastle upon Tyne,
- Royal Marsden Hospital - Dept of Oncology — Sutton,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic or Locally Advanced Unresectable Solid Tumors
Explore by condition: All Metastatic or Locally Advanced Unresectable Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.